Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
With a report showing that 2018 yielded the highest case numbers seen so far of a paralyzing condition largely among children who had been sick with […]